Outcomes of first line chemotherapy in patients with chronic lymphocytic leukemia
Pakistan Journal of Medical Sciences. 2016; 32 (5): 1213-1217
en En
| IMEMR
| ID: emr-183257
Biblioteca responsable:
EMRO
Objective: Chronic lymphocytic leukemia [CLL] is a heterogeneous disease in terms of survival with and without treatment. Many chemo and immunotherapeutic agents are available to treat this indolent disease. Aim of this study was to determine the outcomes of patients with chronic lymphocytic leukemia treated with different available chemotherapeutic regimens
Methods:All patients with diagnosis of CLL from 2008 to 2013 were included. Data were collected from hospital information system. Objective response rate [ORR] in terms of complete or partial response [CR, PR], stable or progressive disease [SD, PD], overall survival [OS], and progression free survival [PFS] were calculated
Results:Fifty seven patients were included; 42 [74%] male and 15 [26%] were female. Patients with Binet stage A 10 [18%]; B 20 [35%] and C were 27[47%]. Median age was 50.9 years. Forty six [80%] were treated and 11[20%] remained on watch and wait. Treatment indications were B symptoms 14 [30%], symptomatic nodal disease 18[39%], thrombocytopenia 4[9%], anemia 7[15%] and doubling of lymphocyte count 3 [7%]. Chemotherapy regimens used were FC in 38 [83%], FCR 5[11%], chlorambucil 2[4%] and CVP in 1[2%] patient. Twenty two [56%] patients had CR, 13[33%] PR, 3[7.6 %] SD, and 1[2.5%] had PD. ORR was 89%. Median PFS was 23.1 months and median 3 years OS was 55%
Conclusion:Majority of patients was in a relatively younger age group and presented with advanced stage disease requiring treatment. Small number of patients received rituximab due to cost. PFS and OS are comparable with published literature
Methods:All patients with diagnosis of CLL from 2008 to 2013 were included. Data were collected from hospital information system. Objective response rate [ORR] in terms of complete or partial response [CR, PR], stable or progressive disease [SD, PD], overall survival [OS], and progression free survival [PFS] were calculated
Results:Fifty seven patients were included; 42 [74%] male and 15 [26%] were female. Patients with Binet stage A 10 [18%]; B 20 [35%] and C were 27[47%]. Median age was 50.9 years. Forty six [80%] were treated and 11[20%] remained on watch and wait. Treatment indications were B symptoms 14 [30%], symptomatic nodal disease 18[39%], thrombocytopenia 4[9%], anemia 7[15%] and doubling of lymphocyte count 3 [7%]. Chemotherapy regimens used were FC in 38 [83%], FCR 5[11%], chlorambucil 2[4%] and CVP in 1[2%] patient. Twenty two [56%] patients had CR, 13[33%] PR, 3[7.6 %] SD, and 1[2.5%] had PD. ORR was 89%. Median PFS was 23.1 months and median 3 years OS was 55%
Conclusion:Majority of patients was in a relatively younger age group and presented with advanced stage disease requiring treatment. Small number of patients received rituximab due to cost. PFS and OS are comparable with published literature
Buscar en Google
Índice:
IMEMR
Idioma:
En
Revista:
Pak. J. Med. Sci.
Año:
2016